Drugs / Bojungikki-tang
Bojungikki-tang
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06249854 | Feb 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Korea Institute of Oriental Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT04907864 | Jan 2020 → Mar 2022 | biliary tract cancer, colorectal cancer, gastric cancer, lung cancer +1 | Kil Yeon Lee | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bojungikki-tang | “Bojungikki-tang 3.75g twice a day” NCT04907864 ↗ |
| Known as | BJIKT | “Bojungikki-tang(BJIKT)” NCT06249854 ↗ |
| Known as | Bojungikki-tang (Kracie Bojungikgitang Extract Fine Granule) | “Bojungikki-tang (Kracie Bojungikgitang Extract Fine Granule)” NCT04907864 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time” NCT06249854 ↗ |
| Route | Oral | “Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day” NCT04907864 ↗ |